Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Lexicon Pharmaceuticals, Inc. (LXRX)
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
lexpharma.com/investors
Company Research
Source: Yahoo! Finance
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Portfolio Optimization Management is pivoting toward a 'lead-to-succeed' strategy, focusing capital on high-impact cardiometabolic and chronic pain programs following a significant organizational repositioning. Performance in 2025 was driven by operational discipline, including a $129.5 million reduction in operating expenses compared to the prior year. The Sonata HCM Phase III trial is differentiated as the only registrational study enrolling both obstructive and nonobstructive hypertrophic cardiomyopathy patients, leveraging a dual SGLT1/2 inhibition mechanism. Strategic positioning for Zynquista in type 1 diabetes relies on a novel regulatory pathway using third-party STENO-1 study data to address a century-long lack of new oral therapies. The company is transitioning from a direct commercial focus for INPEFA to a partnership-heavy model to sustainably support late-stage R&D. O
Show less
Read more
Impact Snapshot
Event Time:
LXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXRX alerts
High impacting Lexicon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LXRX
News
- Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Lexicon: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M [Seeking Alpha]Seeking Alpha
- Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates [Yahoo! Finance]Yahoo! Finance
- Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical UpdatesGlobeNewswire
LXRX
Earnings
- 3/5/26 - Beat
LXRX
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 3/3/26 - Form 4
- LXRX's page on the SEC website